Cadrenal Therapeutics Past Earnings Performance
Past criteria checks 0/6
Cadrenal Therapeutics has been growing earnings at an average annual rate of 60.7%, while the Pharmaceuticals industry saw earnings declining at 0.8% annually.
Key information
60.7%
Earnings growth rate
76.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -78.3% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Cadrenal Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -5 | 4 | 1 |
| 31 Dec 23 | 0 | -8 | 4 | 4 |
| 30 Sep 23 | 0 | -13 | 4 | 4 |
| 30 Jun 23 | 0 | -13 | 4 | 4 |
| 31 Mar 23 | 0 | -12 | 3 | 4 |
Quality Earnings: CVKD is currently unprofitable.
Growing Profit Margin: CVKD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if CVKD's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare CVKD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CVKD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.7%).
Return on Equity
High ROE: CVKD has a negative Return on Equity (-78.27%), as it is currently unprofitable.